UNLABELLED: Glutathione is the predominant endogenous cellular antioxidant, playing a critical role in the cellular defensive response to oxidative stress by neutralizing free radicals and reactive oxygen species. With cysteine as the rate-limiting substrate in glutathione biosynthesis, the cystine/glutamate transporter (system xc(-)) represents a potentially attractive PET biomarker to enable in vivo quantification of xc(-) activity in response to oxidative stress associated with disease. We have developed a system xc(-) substrate that incorporates characteristics of both natural substrates, L-cystine and L-glutamate (L-Glu). L-aminosuberic acid (L-ASu) has been identified as a more efficient system xc(-) substrate than L-Glu, leading to an assessment of a series of anionic amino acids as prospective PET tracers. Herein, we report the synthesis and in vitro and in vivo validation of a lead candidate, (18)F-5-fluoro-aminosuberic acid ((18)F-FASu), as a PET tracer for functional imaging of a cellular response to oxidative stress with remarkable tumor uptake and retention. METHODS: (18)F-FASu was identified as a potential PET tracer based on an in vitro screening of compounds similar to L-cystine and L-Glu. Affinity toward system xc(-) was determined via in vitro uptake and inhibition studies using oxidative stress-induced EL4 and SKOV-3 cells. In vivo biodistribution and PET imaging studies were performed in mice bearing xenograft tumors (EL4 and SKOV-3). RESULTS: In vitro assay results determined that L-ASu inhibited system xc(-) as well as or better than L-Glu. The direct comparison of uptake of tritiated compounds demonstrated more efficient system xc(-) uptake of L-ASu than L-Glu. Radiosynthesis of (18)F-FASu allowed the validation of uptake for the fluorine-bearing derivative in vitro. Evaluation in vivo demonstrated primarily renal clearance and uptake of approximately 8 percentage injected dose per gram in SKOV-3 tumors, with tumor-to-blood and tumor-to-muscle ratios of approximately 12 and approximately 28, respectively. (18)F-FASu uptake was approximately 5 times greater than (18)F-FDG uptake in SKOV-3 tumors. Dynamic PET imaging demonstrated uptake in EL4 tumor xenografts of approximately 6 percentage injected dose per gram and good tumor retention for at least 2 h after injection. CONCLUSION: (18)F-FASu is a potentially useful metabolic tracer for PET imaging of a functional cellular response to oxidative stress. (18)F-FASu may provide more sensitive detection than (18)F-FDG in certain tumors.
UNLABELLED: Glutathione is the predominant endogenous cellular antioxidant, playing a critical role in the cellular defensive response to oxidative stress by neutralizing free radicals and reactive oxygen species. With cysteine as the rate-limiting substrate in glutathione biosynthesis, the cystine/glutamate transporter (system xc(-)) represents a potentially attractive PET biomarker to enable in vivo quantification of xc(-) activity in response to oxidative stress associated with disease. We have developed a system xc(-) substrate that incorporates characteristics of both natural substrates, L-cystine and L-glutamate (L-Glu). L-aminosuberic acid (L-ASu) has been identified as a more efficient system xc(-) substrate than L-Glu, leading to an assessment of a series of anionic amino acids as prospective PET tracers. Herein, we report the synthesis and in vitro and in vivo validation of a lead candidate, (18)F-5-fluoro-aminosuberic acid ((18)F-FASu), as a PET tracer for functional imaging of a cellular response to oxidative stress with remarkable tumor uptake and retention. METHODS: (18)F-FASu was identified as a potential PET tracer based on an in vitro screening of compounds similar to L-cystine and L-Glu. Affinity toward system xc(-) was determined via in vitro uptake and inhibition studies using oxidative stress-induced EL4 and SKOV-3 cells. In vivo biodistribution and PET imaging studies were performed in mice bearing xenograft tumors (EL4 and SKOV-3). RESULTS: In vitro assay results determined that L-ASu inhibited system xc(-) as well as or better than L-Glu. The direct comparison of uptake of tritiated compounds demonstrated more efficient system xc(-) uptake of L-ASu than L-Glu. Radiosynthesis of (18)F-FASu allowed the validation of uptake for the fluorine-bearing derivative in vitro. Evaluation in vivo demonstrated primarily renal clearance and uptake of approximately 8 percentage injected dose per gram in SKOV-3 tumors, with tumor-to-blood and tumor-to-muscle ratios of approximately 12 and approximately 28, respectively. (18)F-FASu uptake was approximately 5 times greater than (18)F-FDG uptake in SKOV-3 tumors. Dynamic PET imaging demonstrated uptake in EL4tumor xenografts of approximately 6 percentage injected dose per gram and good tumor retention for at least 2 h after injection. CONCLUSION: (18)F-FASu is a potentially useful metabolic tracer for PET imaging of a functional cellular response to oxidative stress. (18)F-FASu may provide more sensitive detection than (18)F-FDG in certain tumors.
Authors: Jan Lewerenz; Sandra J Hewett; Ying Huang; Maria Lambros; Peter W Gout; Peter W Kalivas; Ann Massie; Ilse Smolders; Axel Methner; Mathias Pergande; Sylvia B Smith; Vadivel Ganapathy; Pamela Maher Journal: Antioxid Redox Signal Date: 2012-08-03 Impact factor: 8.401
Authors: Vishal S Narang; Giovanni M Pauletti; Peter W Gout; Donna J Buckley; Arthur R Buckley Journal: Anticancer Res Date: 2003 Nov-Dec Impact factor: 2.480
Authors: Norman Koglin; Andre Mueller; Mathias Berndt; Heribert Schmitt-Willich; Luisella Toschi; Andrew W Stephens; Volker Gekeler; Matthias Friebe; Ludger M Dinkelborg Journal: Clin Cancer Res Date: 2011-07-12 Impact factor: 12.531
Authors: Jonathan McConathy; Weiping Yu; Nachwa Jarkas; Wonewoo Seo; David M Schuster; Mark M Goodman Journal: Med Res Rev Date: 2011-07-26 Impact factor: 12.944
Authors: Susanne Müerköster; Alexander Arlt; Maike Witt; André Gehrz; Sieglinde Haye; Christina March; Frauke Grohmann; Kai Wegehenkel; Holger Kalthoff; Ulrich R Fölsch; Heiner Schäfer Journal: Int J Cancer Date: 2003-04-20 Impact factor: 7.396
Authors: H Ahmadian; B Nielsen; H Bräuner-Osborne; T N Johansen; T B Stensbøl; F A Sløk; N Sekiyama; S Nakanishi; P Krogsgaard-Larsen; U Madsen Journal: J Med Chem Date: 1997-10-24 Impact factor: 7.446
Authors: María Domercq; María Victoria Sánchez-Gómez; Catherine Sherwin; Estibaliz Etxebarria; Robert Fern; Carlos Matute Journal: J Immunol Date: 2007-05-15 Impact factor: 5.422
Authors: Oliver C Neels; Klaas P Koopmans; Pieter L Jager; Laya Vercauteren; Aren van Waarde; Janine Doorduin; Hetty Timmer-Bosscha; Adrienne H Brouwers; Elisabeth G E de Vries; Rudi A J O Dierckx; Ido P Kema; Philip H Elsinga Journal: Cancer Res Date: 2008-09-01 Impact factor: 12.701
Authors: Hua Yang; Silvia Jenni; Milena Colovic; Helen Merkens; Carlee Poleschuk; Isabel Rodrigo; Qing Miao; Bruce F Johnson; Michael J Rishel; Vesna Sossi; Jack M Webster; François Bénard; Paul Schaffer Journal: J Nucl Med Date: 2016-10-27 Impact factor: 10.057
Authors: Patrick N McCormick; Hannah E Greenwood; Matthias Glaser; Oliver D K Maddocks; Thibault Gendron; Kerstin Sander; Gayatri Gowrishankar; Aileen Hoehne; Tong Zhang; Adam J Shuhendler; David Y Lewis; Mathias Berndt; Norman Koglin; Mark F Lythgoe; Sanjiv S Gambhir; Erik Årstad; Timothy H Witney Journal: Cancer Res Date: 2018-11-06 Impact factor: 12.701
Authors: Erik S Mittra; Norman Koglin; Camila Mosci; Meena Kumar; Aileen Hoehne; Khun Visith Keu; Andrei H Iagaru; Andre Mueller; Mathias Berndt; Santiago Bullich; Matthias Friebe; Heribert Schmitt-Willich; Volker Gekeler; Lüder M Fels; Claudia Bacher-Stier; Dae Hyuk Moon; Frederick T Chin; Andrew W Stephens; Ludger M Dinkelborg; Sanjiv S Gambhir Journal: PLoS One Date: 2016-02-18 Impact factor: 3.240
Authors: Allison S Cohen; Farah K Khalil; Eric A Welsh; Matthew B Schabath; Steven A Enkemann; Andrea Davis; Jun-Min Zhou; David C Boulware; Jongphil Kim; Eric B Haura; David L Morse Journal: Oncotarget Date: 2017-12-07